Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
October 09, 2024 08:55 ET
|
Kronos Bio, Inc.
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking...
Asset Entities Signs Pivotal Agreement to Build What Could Become The World’s Largest Digital Fitness Community
October 09, 2024 08:00 ET
|
Asset Entities Inc.
DALLAS, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Asset Entities Inc. (“Asset Entities” or “the Company”) (NASDAQ: ASST), a provider of digital marketing and content delivery services across Discord and...
Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders
October 09, 2024 07:30 ET
|
Vanqua Bio
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humansIn healthy volunteers, VQ-101 was well tolerated and achieved...
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
October 08, 2024 08:30 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 08, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will participate in a fireside chat at the...
Nitrase Therapeutics Presents Preclinical Data Demonstrating Antibody Prevents Spread of Pathology of Parkinson’s Disease at SfN’s Neuroscience 2024 Scientific Congress
October 07, 2024 09:00 ET
|
Nitrase Therapeutics
-Development Candidate NDC-0524 is a First-in-Class, Humanized Therapeutic Antibody with High Affinity and Selectivity for Nitrated -Synuclein, which is Rapidly Being Advanced into the Clinic for the...
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
October 07, 2024 08:55 ET
|
Kronos Bio, Inc.
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor...
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 07, 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
YY Group Welcomes Dian Xiao Er as a Partner for Premium Dining Experiences Enhanced by YY Circle’s Staffing Solutions
October 04, 2024 08:00 ET
|
YY Group Holding Limited
YY Group Holdings Limited (YYGH) has entered into a strategic partnership with renowned Chinese restaurant chain Dian Xiao Er.